Everolimus Approved for HR-Positive Breast Cancer

被引：2
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 09期
关键词：
D O I：
10.1158/2159-8290.CD-NB2016-162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：756 / 756
页数：1
相关论文
共 50 条
  • [21] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [22] Efficacy and safety of low-dose everolimus in Chinese HR-positive, HER2-negative metastatic breast cancer patients.
    Shao, Xiying
    Zheng, Yabing
    Chen, Zhan-Hong
    Li, Guangliang
    Jia, Wang Xiao
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
  • [24] Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.
    Shen, Xia-Bo
    Li, Guang-Liang
    Zheng, Ya-Bing
    Chen, Zhan-Hong
    Cao, Wen-Ming
    Shao, Xi-Ying
    Wang, Xiao-Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [26] How we treat HR-positive, HER2-negative early breast cancer
    Lopez-Tarruella, Sara
    Echavarria, Isabel
    Jerez, Yolanda
    Herrero, Blanca
    Gamez, Salvador
    Martin, Miguel
    FUTURE ONCOLOGY, 2022, 18 (08) : 1003 - 1022
  • [27] Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer
    Duso, Bruno Achutti
    Trapani, Dario
    Viale, Giulia
    Criscitiello, Carmen
    D'Amico, Paolo
    Belli, Carmen
    Mazzarella, Luca
    Locatelli, Marzia
    Minchella, Ida
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (03) : 299 - 305
  • [28] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [29] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
  • [30] Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study
    Vernieri, C.
    Nichetti, F.
    Guarneri, V.
    Cortesi, E.
    Moscetti, L.
    Del Mastro, L.
    Fabbri, A.
    Curigliano, G.
    Montemurro, F.
    Losurdo, A.
    Generali, D. G.
    Fabi, A.
    Pedersini, R.
    Ciccarese, M.
    Rocca, A.
    Arpino, G.
    La Verde, N. M.
    Puglisi, F.
    Mariani, L.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S382 - S383
12345